Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA

Amantadine extended release (ER) [GOCOVRI®], an NMDA receptor antagonist, is important treatment option in the management of levodopa-induced dyskinesia (LID) and OFF episodes patients with Parkinson’s disease (PD). Taken at bedtime, amantadine ER provides low plasma levels overnight high concentrations during waking day (i.e. delayed release). In randomized, double-blind, placebo-controlled phase III trials adults PD, once-daily was effective improving LID, reducing time increasing ON without troublesome dyskinesia, compared placebo. Control motor complications evident throughout day, fewer transitions between states. The clinical benefits duration impact were durable long-term treatment. generally well tolerated, including long term, majority adverse events being mild or moderate severity. (PD), a common neurodegenerative disease, associated non-motor symptoms thus exerts considerable burden on health system. Levodopa considered gold standard for PD; however, prolonged use reduced efficacy setting more advanced emergence episodes. Management these often involves trade-off treating one other. capsules (GOCOVRI®), administered once daily are first to be approved USA treat both PD. Evidence has been demonstrated two PD (LID), where it increased relative Benefits over tolerated no new safety concerns identified longer-term use. Given its tolerability profile, LID patients.